一分钟看懂
这是一项关于淋巴瘤的II 期研究，登记的药物或干预包括Biopsy Procedure；Biospecimen Collection；Echocardiography Test；Multigated Acquisition Scan；Osimertinib；Radiologic Examination，当前状态为研究进行中，已停止招募。登记地点显示中国Philadelphia有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Biopsy Procedure；Biospecimen Collection；Echocardiography Test；Multigated Acquisition Scan；Osimertinib；Radiologic Examination · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- ECOG-ACRIN Cancer Research Group · Philadelphia
公开的入选条件
- * Patients must have met applicable eligibility criteria in the Master MATCH Protocol EAY131/ NCI-2015-00054 prior to registration to treatment subprotocol
- * Patient must fulfill all eligibility criteria outlined in MATCH Master Protocol at the time of registration to treatment step (step 1, 3, 5, 7)
- * Patients must have either of the below, or another aberration, as determined via the MATCH Master Protocol:
- Any malignancy except non-small cell lung cancer (NSCLC) with EGFR T790M identified in their tumor, with or without an activating mutation OR
- Any malignancy harboring any of the following mutations: EGFR G719A, G719C, G719D, G719S EGFR L861Q, S786I or an EGFR exon 19 in frame insertion mutation
- * Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment and must have no clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block
- * Patients must have an ECHO or a nuclear study (MUGA or first pass) within 4 weeks prior to registration and must not have a left ventricular ejection fraction (LVEF) \< institutional lower limit of normal (LLN). If the LLN is not defined at a site, the LVEF
- * Patients must not have known hypersensitivity to osimertinib (AZD9291) or compounds of similar chemical or biologic composition or any of the inactive excipients of the tablets
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06303167；登记信息更新于 2026-09-15。